{
  "trial_id": "NCT00396591",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, baseline ascites volume, number of prior paracenteses, performance status, prior treatments, disease stage, baseline blood pressure, baseline laboratory values (e.g., hemoglobin, white blood cell count, platelet count, liver function tests), baseline quality of life scores.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Primary tumor site - Ovaries",
          "disease stage"
        ],
        [
          "Baseline interval of paracentesis",
          "number of prior paracenteses"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) performance status score",
          "performance status"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Time since initial cancer diagnosis",
        "Histology",
        "Histology grade",
        "Prior anticancer surgeries"
      ],
      "remaining_candidate_features": [
        "baseline ascites volume",
        "prior treatments",
        "baseline blood pressure",
        "baseline laboratory values (e.g., hemoglobin, white blood cell count, platelet count, liver function tests)",
        "baseline quality of life scores."
      ]
    },
    "processed-gen-response": "Age, gender, race, baseline ascites volume, number of prior paracenteses, performance status, prior treatments, disease stage, baseline blood pressure, baseline laboratory values (e.g., hemoglobin, white blood cell count, platelet count, liver function tests), baseline quality of life scores."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Number of previous paracenteses, Platinum resistance status, Topotecan/liposomal doxorubicin resistance status, Baseline ascites volume, Baseline performance status, Baseline blood pressure,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Primary tumor site - Ovaries",
          "Region of Enrollment"
        ],
        [
          "Baseline interval of paracentesis",
          "Number of previous paracenteses"
        ],
        [
          "Platinum resistance status",
          "Platinum resistance status"
        ],
        [
          "Topotecan- and/or liposomal doxorubicin-resistant disease",
          "Topotecan/liposomal doxorubicin resistance status"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) performance status score",
          "Baseline performance status"
        ]
      ],
      "remaining_reference_features": [
        "Time since initial cancer diagnosis",
        "Histology",
        "Histology grade",
        "Prior anticancer surgeries"
      ],
      "remaining_candidate_features": [
        "Baseline ascites volume",
        "Baseline blood pressure"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Number of previous paracenteses, Platinum resistance status, Topotecan/liposomal doxorubicin resistance status, Baseline ascites volume, Baseline performance status, Baseline blood pressure"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Region of Enrollment, Platinum resistance status, Topotecan and/or liposomal doxorubicin resistance status, Number of previous paracenteses, Time between paracenteses at baseline, Ascites volume at baseline, CA-125 level at baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) performance status score",
          "Eastern Cooperative Oncology Group (ECOG) Performance Status"
        ],
        [
          "Platinum resistant disease",
          "Platinum resistance status"
        ],
        [
          "Topotecan- and/or liposomal doxorubicin-resistant disease",
          "Topotecan and/or liposomal doxorubicin resistance status"
        ],
        [
          "Baseline interval of paracentesis",
          "Time between paracenteses at baseline"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Race/Ethnicity",
        "Primary tumor site - Ovaries",
        "Time since initial cancer diagnosis",
        "Histology",
        "Histology grade",
        "Prior anticancer surgeries"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Number of previous paracenteses",
        "Ascites volume at baseline",
        "CA-125 level at baseline"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Eastern Cooperative Oncology Group (ECOG) Performance Status, Region of Enrollment, Platinum resistance status, Topotecan and/or liposomal doxorubicin resistance status, Number of previous paracenteses, Time between paracenteses at baseline, Ascites volume at baseline, CA-125 level at baseline."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, platinum-free interval, number of prior chemotherapy regimens, time since last chemotherapy, presence of measurable disease, prior bevacizumab treatment, prior topotecan treatment, prior liposomal doxorubicin treatment, ascites volume at baseline, frequency of paracenteses in the month prior to treatment, quality of life scores at baseline.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Race/Ethnicity",
          "ethnicity"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) performance status score",
          "Eastern Cooperative Oncology Group (ECOG) performance status"
        ],
        [
          "Baseline interval of paracentesis",
          "frequency of paracenteses in the month prior to treatment"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Primary tumor site - Ovaries",
        "Time since initial cancer diagnosis",
        "Histology",
        "Histology grade",
        "Prior anticancer surgeries"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "platinum-free interval",
        "number of prior chemotherapy regimens",
        "time since last chemotherapy",
        "presence of measurable disease",
        "prior bevacizumab treatment",
        "prior topotecan treatment",
        "prior liposomal doxorubicin treatment",
        "ascites volume at baseline",
        "quality of life scores at baseline."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), Eastern Cooperative Oncology Group (ECOG) performance status, platinum-free interval, number of prior chemotherapy regimens, time since last chemotherapy, presence of measurable disease, prior bevacizumab treatment, prior topotecan treatment, prior liposomal doxorubicin treatment, ascites volume at baseline, frequency of paracenteses in the month prior to treatment, quality of life scores at baseline."
  }
}